SCHEMBL4229696

SCHEMBL4229696

CC(C)C(=O)NNC(=O)CCNC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39
ECE1 P42892 3/20 0.37
GAA P10253 1/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 1/20 0.34
CYP2C9 P11712 1/20 0.34
NPC1 O15118 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGAV P06756 1/20 0.33
KDM4E B2RXH2 1/20 0.32
KDM5C P41229 1/20 0.32
EGLN1 Q9GZT9 1/20 0.32
PHF8 Q9UPP1 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32
PRNP P04156 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17087742 0.78 ALDH1A1 (0.34) GAAKMT2AMEN1ALDH1A1NPC1
SCHEMBL21110596 0.78 ADRA1A (0.36) CYP2D6CYP2C19ECE1KMT2AALDH1A1
SCHEMBL4223239 0.78 SMN1; SMN2 (0.46) CYP2D6CYP2C19ECE1GAAKMT2A
SCHEMBL4045977 0.76 MEN1 (0.46) GAAKMT2AMEN1KDM4EPOLB
SCHEMBL1935273 0.75 ALDH1A1 (0.39) CYP2D6CYP2C19ECE1GAAALDH1A1
SCHEMBL11201070 0.75 HDAC3 (0.46) CYP2C19GAAKMT2AMEN1ALDH1A1
SCHEMBL17079154 0.74
SCHEMBL17079155 0.74
SCHEMBL19464346 0.74 GAA (0.38) GAAKMT2AMEN1ALDH1A1NPC1
SCHEMBL3711344 0.73 CYP2C19 (0.38) CYP2D6CYP2C19ECE1ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
EP-3116501-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY Proteostasis Therapeutics, Inc. (US) 2017-01-18 EP disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
WO-2015138909-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-09-17 WO disclosed
US-8354418-B2 Thiazolyl-dihydro-quinazolines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-15 US disclosed
US-20090131424-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-21 US disclosed
US-20070259855-A1 THIAZOLYL-DIHYDRO-INDAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259855-A1 THIAZOLYL-DIHYDRO-INDAZOLE ROR1, RORB, RORA CYP2D6 30/4885CYP2C19 85/4885ECE1 2770/4885
US-20090131424-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE CYP3A7, UGT2B7, UGT1A7 CYP2D6 50/4885CYP2C19 204/4885ECE1 3065/4885
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY CFTR, ABCB4, KEAP1 CYP2D6 4304/4885CYP2C19 4214/4885ECE1 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.